Sign up Australia
Proactive Investors - Run By Investors For Investors

Botanix Pharmaceuticals treats first patient in phase 1b psoriasis study

Uniquely designed patient study which allows the comparison of multiple drugs on the same patient at the same time.
psoriasis
BTX 1308 is Botanix’s third product to commence a patient study in the last 12 months

Botanix Pharmaceuticals Ltd (ASX:BOT) has treated the first patient in its phase 1b BTX 1308 psoriasis patient study.

The study is testing a new formulation of synthetic cannabidiol combined with the company’s novel Permetrex skin delivery technology.

The phase 1b patient study is being conducted in collaboration with BioSkin GmbH, a German clinical contract research organisation and an Australian dermatology clinic.

Bioskin is internationally recognised for their experience with the psoriasis plaque test which is clinically validated and utilised by a number of leading dermatology companies.

The study is designed to assess the safety and efficacy of BTX 1308 on psoriasis plaques or lesions, with the ability to compare multiple formulations and test products at the same time, and on the same patient.

Botanix is advancing multiple clinical programs with near-term milestones

Botanix founder and executive director Matt Callahan said: “We are pleased to have enrolled and treated our first patient in the BTX 1308 psoriasis study.

“The unique design of this patient study which allows us to compare multiple drugs in the same patient at the same time, means that the treatment duration can be shortened, while the quality of data can also be enhanced.

“BTX 1308 is our third product to commence a patient study in the last 12 months, which demonstrates our ability to rapidly add new indications to the pipeline, as we can leverage the studies already successfully completed with synthetic cannabidiol in acne and atopic dermatitis.”

View full BOT profile View Profile

Botanix Pharmaceuticals Ltd Timeline

Related Articles

blood samples in test tubes
October 26 2018
The NYSE-listed company has designed a routine blood test to screen for colorectal and prostate cancers that reduces the need for more invasive colonoscopies and biopsies
Laboratory
June 21 2018
Genedrive has signed sales agreement with Sysmex Corporation for the distribution of the HCV ID to EMEA and Asia Pacific and with Mumbai- based ARKRAY to distribute the kit in India
mri scanner
September 12 2018
IXICO is actively supporting the hunt for breakthrough treatments for Alzheimer’s, Parkinson’s, Huntington’s and multiple sclerosis

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use